Cargando…
Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies
The intranasal lethal mousepox model employing the A/Ncr mouse strain is used to evaluate anti-orthopoxvirus therapies. These infections mimic large droplet transmission and result in 100% mortality within 7-10 days with as little as 1 PFU of ectromelia virus. Unlike the A/Ncr model, humans are less...
Autores principales: | Parker, Scott, Siddiqui, Akbar M., Oberle, Christina, Hembrador, Ed, Lanier, Randall, Painter, George, Robertson, Alice, Buller, R. Mark |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Academic Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801418/ https://www.ncbi.nlm.nih.gov/pubmed/19100593 http://dx.doi.org/10.1016/j.virol.2008.11.015 |
Ejemplares similares
-
Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox – An animal model of smallpox
por: Parker, Scott, et al.
Publicado: (2012) -
Efficacy of therapeutic intervention with an oral ether–lipid analogue of cidofovir (CMX001) in a lethal mousepox model
por: Parker, Scott, et al.
Publicado: (2008) -
Development of CMX001 for the Treatment of Poxvirus Infections
por: Lanier, Randall, et al.
Publicado: (2010) -
Surviving Mousepox Infection Requires the Complement System
por: Moulton, Elizabeth A., et al.
Publicado: (2008) -
Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus
por: Parker, Scott, et al.
Publicado: (2014)